Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niklas Falk

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Drug Discovery Today|January 26, 2011
Exploiting personalized information for reagent selection in drug designJonas Boström, Niklas Falk, Christian Tyrchan
Innere Medizin (Heidelberg, Germany)|July 16, 2025
[Abdominal pain and severely impaired consciousness in a 19-year-old female patient]Anton Kozlov, Cleo Mybes, Niklas Falk, et al.
Glycobiology|January 14, 2004
Tumor attenuation by 2(6-hydroxynaphthyl)-beta-D-xylopyranoside requires priming of heparan sulfate and nuclear targeting of the productsKatrin Mani, Mattias Belting, Ulf Ellervik, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Drug Discovery Today|January 26, 2011
Exploiting personalized information for reagent selection in drug designJonas Boström, Niklas Falk, Christian Tyrchan
Innere Medizin (Heidelberg, Germany)|July 16, 2025
[Abdominal pain and severely impaired consciousness in a 19-year-old female patient]Anton Kozlov, Cleo Mybes, Niklas Falk, et al.
Glycobiology|January 14, 2004
Tumor attenuation by 2(6-hydroxynaphthyl)-beta-D-xylopyranoside requires priming of heparan sulfate and nuclear targeting of the productsKatrin Mani, Mattias Belting, Ulf Ellervik, et al.
Pageof 1